AC Immune SA (ACIU)
ACIU trades on Nasdaq in Health Care, Biotechnology: Pharmaceutical Preparations. Numbers below come from the Nasdaq screener and SEC filings, each with its source.
Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/1651625/000110465926027342/0001104659-26-027342-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLoss), fiscal year ended 2025-12-31. Converted from CHF at 0.8384 per USD (today's ECB or Federal Reserve reference rate).
Profile
| Field | Value |
|---|---|
| Ticker | ACIU on Nasdaq |
| Sector | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations |
| Country | Switzerland |
| IPO year | 2016 |
| SEC CIK | 0001651625 |
| SEC industry code | Pharmaceutical Preparations |
| Incorporated in | Switzerland |
Financials · 2025
| Line | Value |
|---|---|
| Revenue | $4.3M |
| Net income | -$84.0M |
| Operating income | -$82.7M |
| Net margin | -1971.6% |
| Operating margin | -1940.1% |
| Revenue growth | -86.9% |
| Cash | $32.0M |
| Total assets | $184.0M |
| P/E (computed) | Net income was not positive |
| P/S (computed) | 49.9× |
Reported in CHF; shown in US dollars.
Warning signs
| Sign | Finding | Source |
|---|---|---|
| Going concern | No going-concern finding. | 20-F 2026-03-13 |
| Cash and burn | 26.8M CHF cash; operating cash flow -17.3M CHF a quarter. | Report 2025-12-31 |
| Shares outstanding | 101,742,231 (2025-12-31); 100,410,377 a year earlier; 83,620,364 three years earlier. the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures. | Cover page 2025-12-31 |
| Reverse splits, 3 years | None found | None on EDGAR |
| Shelf and offerings, 12 months | 0 S-3/F-3 shelf filings; 0 424B5 takedowns | None on EDGAR |
| Exchange deficiency notices, 12 months | None | None on EDGAR |
| Auditor | PricewaterhouseCoopers AG, Lausanne, Switzerland | PCAOB Form AP 2026-03-31 |
| Late filings, 12 months | None | None on EDGAR |
| Insider trades, 12 months | Bought $31K, sold $59K on the open market | SEC Forms 3/4/5 data sets 2026-09-30 |
From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.
Annual results
| Fiscal year | Revenue | Net income | Op. cash flow | Cash | Total debt | TTM revenue | Source |
|---|---|---|---|---|---|---|---|
| FY 2025 2025-12-31 | 3.6M CHF | -70.4M CHF | -69.3M CHF | 26.8M CHF | No debt tags | 3.6M CHF | 20-F 2026-03-13 |
| FY 2024 2024-12-31 | 27.3M CHF | -50.9M CHF | 65.8M CHF | 36.3M CHF | No debt tags | 27.3M CHF | 20-F 2026-03-13 |
| FY 2023 2023-12-31 | 14.8M CHF | -54.2M CHF | -60.4M CHF | 78.5M CHF | No debt tags | 14.8M CHF | 20-F 2026-03-13 |
| FY 2022 2022-12-31 | 3.9M CHF | -70.8M CHF | -73.6M CHF | 31.6M CHF | No debt tags | 3.9M CHF | 20-F 2025-03-13 |
| FY 2021 2021-12-31 | 0 CHF | -73.0M CHF | -65.7M CHF | 82.2M CHF | No debt tags | 0 CHF | 20-F 2024-03-14 |
| FY 2020 2020-12-31 | 15.4M CHF | -61.9M CHF | -59.5M CHF | 160.9M CHF | No debt tags | 15.4M CHF | 20-F 2023-03-16 |
| FY 2019 2019-12-31 | 110.5M CHF | 45.4M CHF | 55.2M CHF | 193.6M CHF | No debt tags | 110.5M CHF | 20-F 2022-03-22 |
| FY 2018 2018-12-31 | 6.9M CHF | -51.0M CHF | -44.1M CHF | 156.5M CHF | No debt tags | 6.9M CHF | 20-F 2021-03-23 |
From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months). Amounts in CHF.
Key SEC documents
| Document | Form | Filed |
|---|---|---|
| Latest prospectus or offering document FORM 424B5 | 424B5 | 2024-08-06 |
| Latest annual report | 20-F | 2026-03-13 |
| Latest quarterly / interim | 6-K | 2026-11-04 |
Source: SEC EDGAR submissions feed, 313 recent filings. All filings on EDGAR.
Price moves
| Window | Return |
|---|---|
| 1 week | -4.5% |
| 1 month | -11.3% |
| 3 months | -17.1% |
| Year to date | -32.2% |
| 1 year | -34.1% |
| From 52-week high | -42.4% |
Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.
Peers in Biotechnology: Pharmaceutical Preparations
| Ticker | Company | Price | Day | Market cap |
|---|---|---|---|---|
| YARW | Yarrow Bioscience Inc. | $13.93 | -22.74% | $212.2M |
| VOGX | Vogenx Inc | $14.38 | -13.74% | $213.6M |
| CYPH | Cypherpunk Technologies Inc. | $1.93 | +2.94% | $207.4M |
| SIGA | SIGA Technologies Inc. | $2.85 | +4.01% | $204.8M |
| DRUG | Bright Minds Biosciences Inc. | $22.61 | -2.16% | $222.0M |
| BCYC | Bicycle Therapeutics plc | $3.18 | -5.64% | $222.9M |
| GLSI | Greenwich LifeSciences Inc. | $13.76 | -7.90% | $202.0M |
| IMRX | Immuneering Corporation | $3.52 | -5.12% | $228.0M |
The full dossier has every filing, three years of financials, private raises and the people who signed them.
Open the full dossier